Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.

BACKGROUND: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. MATERIAL AND METHODS: From January 2001 to September 2006 we treated with imatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Girmenia, Corrado, Latagliata, Roberto, Loglisci, Giuseppina, Santopietro, Michelina, Federico, Vincenzo, Petrucci, Luigi, Serrao, Alessandra, Salaroli, Adriano, Alimena., Giuliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113277/
https://www.ncbi.nlm.nih.gov/pubmed/21713076
http://dx.doi.org/10.4084/MJHID.2011.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113277/
https://www.ncbi.nlm.nih.gov/pubmed/21713076
http://dx.doi.org/10.4084/MJHID.2011.021

Ejemplares similares